XTL Financial Statements From 2010 to 2024
XTLB Stock | ILS 5.90 0.10 1.72% |
Check XTL Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XTL Biopharmaceutica's main balance sheet or income statement drivers, such as , as well as many indicators such as . XTL financial statements analysis is a perfect complement when working with XTL Biopharmaceutica Valuation or Volatility modules.
XTL |
XTL Biopharmaceuticals Company Price To Earning Analysis
XTL Biopharmaceutica's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current XTL Biopharmaceutica Price To Earning | 558.33 X |
Most of XTL Biopharmaceutica's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XTL Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition |
Based on the latest financial disclosure, XTL Biopharmaceuticals has a Price To Earning of 558 times. This is much higher than that of the sector and significantly higher than that of the Price To Earning industry. The price to earning for all Israel stocks is notably lower than that of the firm.
XTL Biopharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XTL Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare XTL Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XTL Biopharmaceutica competition to find correlations between indicators driving XTL Biopharmaceutica's intrinsic value. More Info.XTL Biopharmaceuticals is rated first in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value XTL Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for XTL Biopharmaceutica's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About XTL Biopharmaceutica Financial Statements
XTL Biopharmaceutica stakeholders use historical fundamental indicators, such as XTL Biopharmaceutica's revenue or net income, to determine how well the company is positioned to perform in the future. Although XTL Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in XTL Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on XTL Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in XTL Biopharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. XTL BIOPHARMACEUTI is traded on Tel Aviv Stock Exchange in Israel.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in XTL Stock
XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.